Last reviewed · How we verify
HL036
At a glance
| Generic name | HL036 |
|---|---|
| Sponsor | HanAll BioPharma Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease (PHASE3)
- A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes (PHASE2)
- A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye (PHASE3)
- A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye (PHASE3)
- A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes (PHASE3)
- Phase 1 Study for Safety and Tolerability of HL036 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HL036 CI brief — competitive landscape report
- HL036 updates RSS · CI watch RSS
- HanAll BioPharma Co., Ltd. portfolio CI